Results 141 to 150 of about 16,542 (247)

Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
Dupilumab improved all histological, symptomatic, and endoscopic outcomes assessed at Week 24 versus placebo in patients with eosinophilic oesophagitis, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities.
Evan S. Dellon, Marc E. Rothenberg, Jonathan M. Spergel, Albert J. Bredenoord, Antonella Cianferoni, Changming Xia, Margee Louisias, Allen Radin   +7 more
wiley   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source

Modern Possibilities of Usage Dupilumab in Children

Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children.
Aishan Е. Ibaduiiaeva, Anastasiya V. Fayans, Dayana G. Bayburdyan, Anastaiya N. Nikovaeva, Marina I. Korniiova, Saak G. Serobyan, Dmitriy V. Kaiinin, Eieonora Yu. Ivanova, Irina R. Fomina, Kirill S. Gusev, Anna A. Kosova, Ziki Sh. Bukhsaev   +11 more
core   +1 more source

The Immunomodulatory Power of Dupilumab: -Implications for Keloid Scar Treatment

Keloids are pathologic responses to cutaneous injury. Current treatments, such as topical and intralesional steroids and even surgical excision, have limited efficacy, creating a demand for improved therapies.
Jaalouk, Dana, Algarin, Yanci A, Nouri, Keyvan, Pulumati, Anika   +3 more
core   +2 more sources

Dupilumab treatment for pruritus-associated cutaneous sarcoidosis

Sarcoidosis is a chronic multisystemic, inflammatory disease characterized by the formation of noncaseating granulomas, with cutaneous involvement in a fraction of patients.
Pandher, Karan, Gao, David, Lim, Henry W, Choi, Sooin   +3 more
core  

Comparative Real-World Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients with Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study. [PDF]

Drug Des Devel Ther
Liao KM, Huang SC, Wu JY, Kuo CY, Hsu WH, Kostikas K, Lai CC.   +6 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Anthropometric patterns in children with moderate‐to‐severe atopic dermatitis: Cross‐sectional insights from the TREATkids cohort

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The relationship between atopic dermatitis (AD), weight, height, and body mass index (BMI) in children and adolescents and the impact of systemic treatments is controversial. We report the distribution of weight, height, and BMI in the German TREATkids cohort compared to a standardized German cohort (Kromeyer‐Hauschild)
Barbara Kind, Doreen Siegels, Hagen Ott, Susanne Abraham, René Sachse, Katharina Lönnecke, Inken Harder, Annice Heratizadeh, Katja Nemat, Christian Vogelberg, Dora Stölzl, Ines Gellhaus, Susanne Lau, Mehrak Yoosefi Moridani, Thomas Werfel, Stephan Weidinger, Jochen Schmitt, the TREATgermany study group   +17 more
wiley   +1 more source

Sinonasal Histopathological Changes After 12 Months of Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps. [PDF]

Med Sci (Basel)
Kamiński B, Ochab D, Kopczyński J, Łacwik P, Bętkowska M, Flaga S, Pałczyński C.   +6 more
europepmc   +1 more source

Phenotypes and clinical outcomes in children with moderate‐to‐severe atopic dermatitis across diverse ancestries: a Spanish multicenter observational study and cluster analysis (AD‐SKINS Project)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles, Adrià Plana‐Pla, Asunción Vicente, Eulàlia Baselga, Helena Iznardo, Esther Roé, Miquel Casals‐Andreu, Maria Sin‐Soler, Josep A. Pujol‐Montcusí, Maria del Mar Cordellat‐Martínez, Xavier Soria‐Gili, Maria del Mar Tapias‐Terré, Marta Bertolin‐Colilla, Nidia Planella‐Fontanillas, Laura Marques‐Martín, Mónica Munera‐Campos, Maria Fabregat‐Pratdepadua, Carolina S. Prat‐Torres, Marta Ivars, Luisa F. Montenegro‐Morillo, Isabel Bielsa‐Marsol, Jose‐Manuel Carrascosa‐Carrillo   +21 more
wiley   +1 more source